Peptides and compounds that bind to the IL-5 receptor
First Claim
Patent Images
1. A compound comprising a sequence of amino acids selected from the groups consisting ofTGGGDGYVX3VE X4 ARCPTCK (residues 32–
- 50 of SEQ ID NO;
1);
EGYVX3VE X4 ARCPTCK (residues 36–
50 of SEQ ID NO;
2);
EGYVX3VE X4 ARCPTCR (residues 36–
50 of SEQ ID NO;
3);
GYVX3VE X4 ARCPTCG (residues 36–
50 of SEQ ID NO;
4);
EGYVX3VE X4 ARCPTCG (residues 36–
50 of SEQ ID NO;
5);
GYVX3VE X4 ARCPTCR (residues 37–
50 of SEQ ID NO;
6); and
EGYVX3VE X4 AACPTCR (residues 36–
50 of SEQ ID NO;
7)wherein X3 is Cys, Lys, or Dpr, and X4 is Nal, Trp, or Phe.
0 Assignments
0 Petitions
Accused Products
Abstract
Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX3VE X4 ARCPTCK, EGYVX3VE X4 ARCPTCK, EGYVX3VE X4 ARCPTCR, GYVX3VE X4 ARCPTCG, EGYVX3VE X4 ARCPTCG, GYVX3VE X4 ARCPTCR, and EGYVX3VE X4 AACPTCR, and methods of using the same, are described and claimed.
-
Citations
24 Claims
-
1. A compound comprising a sequence of amino acids selected from the groups consisting of
TGGGDGYVX3VE X4 ARCPTCK (residues 32– - 50 of SEQ ID NO;
1);EGYVX3VE X4 ARCPTCK (residues 36–
50 of SEQ ID NO;
2);EGYVX3VE X4 ARCPTCR (residues 36–
50 of SEQ ID NO;
3);GYVX3VE X4 ARCPTCG (residues 36–
50 of SEQ ID NO;
4);EGYVX3VE X4 ARCPTCG (residues 36–
50 of SEQ ID NO;
5);GYVX3VE X4 ARCPTCR (residues 37–
50 of SEQ ID NO;
6); andEGYVX3VE X4 AACPTCR (residues 36–
50 of SEQ ID NO;
7)wherein X3 is Cys, Lys, or Dpr, and X4 is Nal, Trp, or Phe. - View Dependent Claims (2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 19, 22)
- 50 of SEQ ID NO;
-
7. A compound comprising a sequence of amino acids selected from the groups consisting of
X1-TGGGDGYVX3VEX4ARCPTCK-X2 (residues 32– - 50 of SEQ ID NO;
1);X1-EGYVX3VEX4ARCPTCK-X2 (residues 36–
50 of SEQ ID NO;
2);X1-EGYVX3VEX4ARCPTCR-X2 (residues 36–
50 of SEQ ID NO;
3);X1-GYVX3VEX4ARCPTCG-X2 (residues 36–
50 of SEQ ID NO;
4);X1-EGYVX3VEX4ARCPTCG-X2 (residues 36–
50 of SEQ ID NO;
5);X1-GYVX3VEX4ARCPTCR-X2 (residues 37–
50 of SEQ ID NO;
6); andX1-EGYVX3VEX4AACPTCR-X2 (residues 36–
50 of SEQ ID NO;
7)wherein X1 is hydrogen or acyl;
X2 is —
NH2 or —
OH wherein —
NH2 indicates that the carboxy terminus of the compound has been amidated and —
OH indicates that the carboxy terminus of the compounds has not been derivatized;
X3 is Cys, Lys, or Dpr, and X4 is Nal, Trp, or Phe.- View Dependent Claims (8, 9, 20, 23)
- 50 of SEQ ID NO;
-
10. A compound comprising an amino acid sequence selected from the group consisting of
(H)-TGGGDGYVCVEWARCPTCK-(OH) (residues 32– - 50 of SEQ ID NO;
8);(Ac)-EGYV(Dpr)VEWARCPTCR-(NH2) (residues 36–
50 of SEQ ID NO;
9);(Ac)-EGYVCVEWAACPTCR-(NH2) (residues 36–
50 of SEQ ID NO;
10);(Ac)-EGYVCVEWARCPTCK-(NH2) (residues 36–
50 of SEQ ID NO;
11);(Ac)-EGYVCVEWARCPTCK-(OH) (residues 36–
50 of SEQ ID NO;
11);(Ac)-EGYVCVEWARCPTCR-(NH2) (residues 36–
50 of SEQ ID NO;
12);(Ahx)-EGYVCVEWARCPTCR-(NH2) (residues 36–
50 of SEQ ID NO;
12);(H)-EGYVCVEFARCPTCG-(NH2) (residues 36–
50 of SEQ ID NO;
13);(H)-EGYVCVEFARCPTCR-(OH) (residues 36–
50 of SEQ ID NO;
14);(H)-EGYVCVEWARCPTCG-(NH2) (residues 36–
50 of SEQ ID NO;
15);(H)-EGYVCVEWARCPTCK-(NH2) (residues 36–
50 of SEQ ID NO;
11);(H)-EGYVCVEWARCPTCK-(OH) (residues 36–
50 of SEQ ID NO;
11);(Ac)-EGYVCVEWARCPTCR-(OH) (residues 36–
50 of SEQ ID NO;
12);(H)-EGYVCVEWARCPTCR-(NH2) (residues 36–
50 of SEQ ID NO;
12);(H)-EGYVCVEWARCPTCR-(OH) (residues 36–
50 of SEQ ID NO;
12);(H)-EGYVKVEWARCPTCR-(OH) (residues 36–
50 of SEQ ID NO;
16);(H)-GYVCVEFARCPTCG-(NH2) (residues 37–
50 of SEQ ID NO;
17); and(H)-GYVCVEWARCPTCR-(OH) (residues 37–
50 of SEQ ID NO;
18)wherein —
(NH2) indicates that the carboxy terminus of the compound has been amidated, —
(OH) indicates that the carboxy terminus of the compound has not been derivatized, (Ac) indicates that the amino terminus of the compound has been acetylated, and (Ahx)- indicates that the amino terminus of the compound has been acylated with aminohexanoic acid.- View Dependent Claims (11, 12, 21, 24)
- 50 of SEQ ID NO;
Specification